MARKET WIREYahoo Finance • 10h ago
COLL vs. DSNKY: Which Stock Is the Better Value Option?Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
Why COLL Stock slipped -0.96% Today — RQD Quant Desk Flash
$23.80 -0.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.71
Collegium Pharmaceutical Inc. (COLL) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $782.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on COLL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $23.80 (-0.96% 1D, market cap $782.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, COLL ranks #187 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COLL compare to HELP and AVBP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable C- (59/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M) and AVBP (ArriVent BioPharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COLL?
▼
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.71 (-0.36%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 42% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COLL)Realized 20D OHLCV Swing Band: ±7%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY COLL SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 42% FCF Margin ($327.6M FCF) & 59.3% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)
Macro rate sensitivity & RSI-14 (59) create a -12 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$22.05+4.4% Next Q
51
Q2 (-2Q)Grade C-$23.01+0.9% Next Q
54
Q3 (-1Q)Grade C$23.21+2.5% Next Q
56
CurrentGrade C-$23.80+0.2% Hist 90D α
59
Trajectory: C- (51) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the COLL Bull Thesis Could Fail
Even with a 59/100 (C-) score, COLL faces multiple-compression risk if 12.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.24) or 200D SMA ($33.12) invalidates the momentum regime and cuts Target Base ($23.91) toward Bear Floor ($18.65).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $COLL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “COLL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why COLL Stock slipped -0.96% Today — RQD Quant Desk Flash
Collegium Pharmaceutical Inc. (COLL) slipped -0.96% to $23.80, trading at 8% of its 52-week range ($21.43 – $50.79). Solid 59% profit margin (85% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 8% of its 52-week range ($21.43 – $50.79) with RSI-14 at 59 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7% around $23.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 59.3% gross margin and $327.6M annual free cash flow.
Live COLL Headlines & Catalysts
RISK WATCHSeeking Alpha • 13h ago
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)Seeking Alpha report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 16h ago
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocksYahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 19h ago
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 22h ago
An investor reports 5% or less of Collegium Pharmaceutical (COLL) and shares voting power.Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHDYahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A planned 2027 soccer program will train coaches to better support kids with ADHDStock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Operating Leverage and Financial Strength Anchor Champion Homes (SKY) Investment ThesisThird Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
CATALYSTYahoo • 3d ago
Versigent (VGNT) is Unlocking Value Through Independent Growth and Capital AllocationThird Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (COLL Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
COLL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.17%▲ RESISTANCE BREAKOUT
2026-11-02O $23.23H $24.03L $23.23C $23.80VOL 656.5K
RES: $22.36SUP: $16.05SMA50: $23.24SMA200: $33.12
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
COLL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
3.2%/yr Implied 5Y Growth
vs. +23.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on COLL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for COLL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COLL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COLL)
Health Care Rank #187 of 1016
⚔️ HELP vs COLL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (COLL vs. HELP, AVBP, ARDX, ANNX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Collegium Pharmaceutical Inc. (COLL) ranks #187 by composite RQD confidence (59/100, grade C-) and #389 by equity capitalization ($782.3M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COLL
ACTIVE
Collegium Pharmaceutical Inc. | C- | 59/100 | 12.4x | 59.3% | 85.0% | -0.96% | $782.3M | Benchmark Subject |
| HELP Helus Pharma Inc. | D+ | 54/100 | — | — | — | -1.07% | $782.5M | /help-vs-coll → |
| AVBP ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -6.77% | $786.5M | /avbp-vs-coll → |
| ARDX Ardelyx Inc. | E | 24/100 | — | 90.3% | -32.7% | -2.26% | $772.5M | /ardx-vs-coll → |
| ANNX Annexon Inc. | E | 30/100 | — | — | -35.0% | +1.00% | $760.2M | /annx-vs-coll → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001267565In its most recent audited fiscal period (FY2025, filed 2025-12-31), Collegium Pharmaceutical Inc. (COLL) reported GAAP revenue of $780.6M (+23.6% vs. FY2024 revenue of $631.4M , and +37.7% cumulative change since FY2023) , GAAP net income of $63.0M, operating cash flow of $329.3M, and free cash flow of $327.6M (+61.1% YoY). On the balance sheet, COLL closed FY2025 with $1.66B in total assets against $0 in total debt (Altman Z-Score: 1.27, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $780.6M | $63.0M | $329.3M | $327.6M | $1.66B | — |
| FY2024 (FY) | 2024-12-31 | $631.4M | $69.0M | $205.0M | $203.3M | $1.66B | — |
| FY2023 (FY) | 2023-12-31 | $566.8M | $48.0M | $274.7M | $274.7M | — | — |
3. COLL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $23.80 (-0.96% 1D, market cap $782.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, COLL ranks #187 in composite RQD confidence.
How does COLL compare to HELP and AVBP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable C- (59/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M) and AVBP (ArriVent BioPharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COLL?
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COLL trading relative to its 50-day, 200-day, and 52-week technical levels?
COLL last traded at $23.80 (-0.96% on volume of 401,954 shares), positioning the stock +2.41% above its 50-day simple moving average ($23.24) and -28.14% below its 200-day simple moving average ($33.12). Across its 52-week range of $21.43 to $50.79, COLL sits at the 8.1% percentile with a 14-day RSI of 59.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.0% ($22.13 to $25.47).
COLL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is COLL stock moving today?
Why COLL Stock slipped -0.96% Today — RQD Quant Desk Flash. Solid 59% profit margin (85% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
COLL — Collegium Pharmaceutical Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:32:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, COLL scores 59 out of 100, earning a letter grade of C- and the verdict label "Roarable Hold — Cautious Neutral." The five pillars are:
- Fundamental Cash Engine: 16 / 20. Per the RQD rating, this pillar reflects ROIC of 85% and an FCF yield of 0%. The high return on invested capital is a meaningful upside driver, while the 0% FCF yield means the rating does not credit free-cash-flow yield at current market value.
- Whale 13F Flow: 8 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The modest score indicates limited evidence of strong institutional conviction in the source data.
- Insider Conviction: 15 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is the second-strongest pillar and suggests comparatively supportive insider-side signals.
- Macro Regime Fit: 8 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. The score signals the stock's exposure to broader market movement is not offset by a clear macro tailwind.
- Forensic Balance Sheet: 12 / 20. Per the RQD rating, this pillar reflects an Altman Z of 1.27, a Piotroski F of 7/9, and a Debt/Equity of 0.5. The Piotroski reading is solid, while the Altman Z sits in a range that warrants caution.
For a prospective investor, the blend implies a stock with strong capital efficiency and supportive insider signals, offset by weaker institutional flow, neutral-to-weak macro fit, and a balance-sheet read that is mixed rather than clean. The valuation tradeoff is visible in the market data: a trailing P/E of 12.4 and forward P/E of 10.4 are low in absolute terms, but the 0% FCF yield means cash-based valuation support is not reflected in the rating. The verdict label of "Cautious Neutral" reflects this balance rather than a directional call.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $179.6M | $63.0M | N/A | $327.6M | $231.3M | N/A |
| FY 2024 | $631.4M | $169.9M | $69.0M | N/A | $203.3M | $70.6M | N/A |
| FY 2023 | $566.8M | $167.0M | $48.0M | N/A | $274.7M | N/A | N/A |
Per the SEC financials, revenue rose from $566.8M in FY 2023 to $780.6M in FY 2025, while operating income moved from $167.0M to $179.6M over the same span. Per the market data, gross margin is 59.3%, operating margin is 23%, and net margin is 8.1%, with ROIC at 85%. Per the RQD rating, the Altman Z is 1.27 and the Piotroski F is 7/9. Per the SEC financials, FY 2025 net income of $63.0M was below FY 2024's $69.0M despite higher revenue, and reported cash increased to $231.3M from $70.6M. Debt is Not available in source data for any period, and the Debt/Equity of 0.5 is cited only in the RQD rating.
Recent Catalysts & News Wire Analysis
Per the recent news wire, the items are:
- RISK WATCH (RED): A Seeking Alpha report headlined around a narrow guidance cut, framed as trading under 3x cash earnings.
- MARKET WIRE (YELLOW): A Q2 2026 earnings call transcript (Benzinga), a Q2 earnings comparison versus branded pharmaceutical peers (Yahoo Finance), a Form-type ownership disclosure from Stock Titan regarding a holder reporting 5% or less of shares and voting power, a repositioning story from pain management toward ADHD (Yahoo Finance), and a comparative value piece versus DSNKY (Yahoo Finance).
Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.
Open Questions
- What is the reported debt balance, given that debt is N/A across all three periods while Debt/Equity of 0.5 is cited in the RQD rating?
- What drove the narrow guidance cut referenced in the RISK WATCH headline, and how does it relate to the FY 2025 net income decline?
- Why is FCF yield 0% in the market data when reported FY 2025 free cash flow is $327.6M against a market cap of $782.3M?
- What is the EPS for FY 2023 through FY 2025, which the financials table lists as N/A?
- What is the composition of revenue by product, and how much of the ADHD repositioning is reflected in current results?
COLL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Collegium Pharmaceutical Inc. (COLL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 10h ago
COLL vs. DSNKY: Which Stock Is the Better Value Option? Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 13h ago
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL) Seeking Alpha report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 16h ago
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 19h ago
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript Benzinga report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 22h ago
An investor reports 5% or less of Collegium Pharmaceutical (COLL) and shares voting power. Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A planned 2027 soccer program will train coaches to better support kids with ADHD Stock Titan report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect? Yahoo Finance report covering Collegium Pharmaceutical Inc. (COLL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
COLL Bull vs. Bear Conversation Board — What's Your Call at $23.80?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COLL 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $25.95 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is COLL (C- • RQD 59/100) a Buy at $24.03?
Welcome to the COLL (Collegium Pharmaceutical Inc.) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $18.50 (-23.0%)
Spot @ $24.03 Pump the brakes on COLL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on COLL, but look at what you are paying: 12.4x trailing P/E with 59.3% gross margins. Unless Collegium Pharmaceutical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $30.28 (+26.0%)
Spot @ $24.03 COLL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on COLL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $24.03 (52-wk range $21.43 - $50.79), any beat on forward guidance forces shorts and underweight funds to chase.